Merck’s Q4 and full-year 2022 earnings call and the accompanying financial results suggest several positive factors that are likely to influence the stock price in the short term:

1. **Strong Revenue Growth**: Merck reported a 22% increase in full-year 2022 worldwide sales, driven by key pillars such as Oncology, Vaccines, and Hospital Acute Care. This sustained growth is expected to continue into 2023, with projected revenues between $57.2 billion and $58.7 billion[2][4].

2. **Pipeline Advancements**: Significant progress in the pipeline, including new approvals for KEYTRUDA, positive Phase 2 results for a personalized mRNA therapeutic cancer vaccine, and advancements in cardiovascular and vaccine programs, indicate a robust innovation engine that will drive future growth[4].

3. **Guidance and Outlook**: The company provided strong guidance for 2023, expecting underlying revenue growth of 7% to 10% excluding the impact of LAGEVRIO and foreign exchange. This confidence in continued growth across key segments is positive for investor sentiment[4].

4. **Business Development and Strategic Initiatives**: Merck’s disciplined approach to business development, including new partnerships and acquisitions, such as the deal with Moderna and the expansion of the agreement with Kelun Biotech, further enhances the company’s growth potential[4].

Given these positive factors, including strong revenue growth, significant pipeline advancements, and a confident outlook for 2023, the stock is likely to experience a positive impact in the short term.

**[1]**